{"organizations": [], "uuid": "d7501a83a0feada3a5673046b7168aca085240af", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-emergent-biosolutions-q4-earnings/brief-emergent-biosolutions-q4-earnings-per-share-0-67-idUSASB0C761", "country": "US", "domain_rank": 408, "title": "BRIEF-Emergent BioSolutions Q4 Earnings Per Share $0.67", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-23T00:02:00.000+02:00", "replies_count": 0, "uuid": "d7501a83a0feada3a5673046b7168aca085240af"}, "author": "", "url": "https://www.reuters.com/article/brief-emergent-biosolutions-q4-earnings/brief-emergent-biosolutions-q4-earnings-per-share-0-67-idUSASB0C761", "ord_in_thread": 0, "title": "BRIEF-Emergent BioSolutions Q4 Earnings Per Share $0.67", "locations": [], "entities": {"persons": [{"name": "sha", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "emergent biosolutions inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 22 (Reuters) - Emergent BioSolutions Inc:\n* EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND TWELVE MONTHS 2017 FINANCIAL RESULTS\n* Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.74\n* Q4 EARNINGS PER SHARE $0.67 * Q4 REVENUE ROSE 28 PERCENT TO $193.8 MILLION * SEES FY 2018 REVENUE $715 MILLION TO $755 MILLION * SEES 2018 NET INCOME OF $95 MILLION TO $110 MILLION * SEES 2018 ADJUSTED NET INCOME OF $110 MILLION TO $125 MILLION\n* SEES ‍Q1 2018 TOTAL REVENUE OF $125 MILLION TO $150 MILLION​\n* EMERGENT BIOSOLUTIONS SAYS IS TARGETING 2020 TOTAL REVENUE OF $1 BILLION\n* TARGETING 2020 NET INCOME AT LEAST 14 PERCENT OF TOTAL REVENUE​ Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-02-23T00:02:00.000+02:00", "crawled": "2018-02-23T00:11:46.000+02:00", "highlightTitle": ""}